<2-(3-hydroxy-2-pyridyl)-4-thiazolyl>acetic acid | 171017-51-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: <2-(3-hydroxy-2-pyridyl)-4-thiazolyl>acetic acid
• 英文别名: 2-(3-Hydroxy-2-pyridinyl)-4-thiazoleacetic Acid；2-[2-(3-hydroxypyridin-2-yl)-1,3-thiazol-4-yl]acetic acid
• CAS: 171017-51-9
• 化学式: C₁₀H₈N₂O₃S
• 分子量: 236.251
• InChiKey: CMBJQRMMGWSGSR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  <2-(3-hydroxy-2-pyridyl)-4-thiazolyl>acetic acid 在 三乙基硅烷 、 morpho CDI 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 29.0h， 生成 (6R,7R)-3-chloro-7-<2-(3-hydroxy-pyridyl)-4-thiazolyl>acetylamino-8-oxo-5-thia-1-azabicyclo<4.2.0>oct-2-ene-2-carboxylic acid
  参考文献：
  名称：

  Lin, Ho-Shen; Rampersaud, Ashraff A.; Flokowitsch, Jane E., Journal of the Chinese Chemical Society, 1995, vol. 42, # 5, p. 833 - 846

  摘要：

  DOI：
• 作为产物：
  描述：

  3-羟基吡啶酰胺 在 劳森试剂 、 lithium hydroxide 、 lithium bromide 作用下， 以 四氢呋喃 、 甲醇 、 1,2-二氯乙烷 为溶剂， 反应 5.5h， 生成 <2-(3-hydroxy-2-pyridyl)-4-thiazolyl>acetic acid
  参考文献：
  名称：

  Lin, Ho-Shen; Rampersaud, Ashraff A.; Flokowitsch, Jane E., Journal of the Chinese Chemical Society, 1995, vol. 42, # 5, p. 833 - 846

  摘要：

  DOI：

文献信息

• 7-substituted-amino-3-substituted-3-cephem-4-carboxylic acids
  申请人：Eli Lilly and Company

  公开号：US05525599A1

  公开（公告）日：1996-06-11

  The invention provides compounds of the formula ##STR1## wherein X is CH.sub.2, S or O; R.sub.1 is a 3 position substituent such as hydrogen, hydroxy, halo, trifluoromethyl, C.sub.2 F.sub.5, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 substituted alkyl, C.sub.1 -C.sub.6 alkenyl, C.sub.1 -C.sub.6 alkynyl, CH.sub.2 O(CO)R', CH.sub.2 O(CO)NH.sub.2, CO.sub.2 R', thio(C.sub.1 -C.sub.6)alkyl, thio(C.sub.1 C.sub.6)alkenyl, oxo(C.sub.1 -C.sub.6)alkyl, phosphine oxide, quaternary ammonium group, substituted or unsubstituted thiazolothio, or oxo(C.sub.1 -C.sub.6)alkenyl; wherein R' is hydrogen, C.sub.1 -C.sub.6 alkyl, or C.sub.1 -C.sub.6 alkenyl; R.sub.2 is hydrogen or a carboxy protecting group; R.sub.3 is ##STR2## (CH.sub.2).sub.n ; wherein R.sub.6 is hydrogen Me, CH.sub.2 F, CF.sub.3, C.sub.2 H.sub.5, CH.sub.2 CH.sub.2 F, CH.sub.2 CF.sub.3, C.sub.2 F.sub.5, CH.sub.2 CO.sub.2 R', CH.sub.2 CONH.sub.2, C(Me).sub.2 CO.sub.2 R', or C(Me).sub.2 CONH.sub.2 ; and n is 0-5; R.sub.4 is ##STR3## wherein Z is O, S, NH, or CH.sub.2 ; Y is CH or N; and R.sub.7 is hydrogen, C.sub.1 -C.sub.6 alkyl, CONH.sub.2, or CO.sub.2 R'; and R.sub.5 is ##STR4## wherein R.sub.8 is CH, N, COH, CO(C.sub.1 -C.sub.6 alkyl) CSH, or CNH.sub.2 ; and R.sub.9 is R.sub.8 as defined; said R.sub.5 optionally substituted 1-4 times with halo, OH, SH, NH.sub.2, NO.sub.2, CH.sub.3, C.sub.2 H.sub.5, CO.sub.2 R', CONH.sub.2, SO.sub.3 H, or SO.sub.2 NHR'; and salts thereof. Also, pharmaceutical formulations and methods for treating bacterial infections in man or other animals using the above compounds are disclosed.

  该发明提供了以下结构的化合物：其中X为CH₂、S或O；R₁为3位取代基，如氢、羟基、卤素、三氟甲基、C₂F₅、C₁-C₆烷基、C₁-C₆取代烷基、C₁-C₆烯基、C₁-C₆炔基、CH₂O(CO)R'、CH₂O(CO)NH₂、CO₂R'、硫代(C₁-C₆)烷基、硫代(C₁-C₆)烯基、氧代(C₁-C₆)烷基、膦氧化物、季铵基团、取代或未取代噻唑硫、或氧代(C₁-C₆)烯基；其中R'为氢、C₁-C₆烷基或C₁-C₆烯基；R₂为氢或羧基保护基；R₃为(CH₂)n；其中R₆为氢、甲基、CH₂F、CF₃、C₂H₅、CH₂CH₂F、CH₂CF₃、C₂F₅、CH₂CO₂R'、CH₂CONH₂、C(Me)₂CO₂R'或C(Me)₂CONH₂；n为0-5；R₄为；其中Z为O、S、NH或CH₂；Y为CH或N；R₇为氢、C₁-C₆烷基、CONH₂或CO₂R'；R₅为；其中R₈为CH、N、COH、CO(C₁-C₆烷基)、CSH或CNH₂；R₉为所定义的R₈；所述的R₅可选择地1-4次取代为卤素、OH、SH、NH₂、NO₂、CH₃、C₂H₅、CO₂R'、CONH₂、SO₃H或SO₂NHR'；及其盐。此外，还公开了利用上述化合物治疗人类或其他动物的细菌感染的药物配方和方法。
• US5525599A
  申请人：——

  公开号：US5525599A

  公开（公告）日：1996-06-11
• US5527792A
  申请人：——

  公开号：US5527792A

  公开（公告）日：1996-06-18
• US5620968A
  申请人：——

  公开号：US5620968A

  公开（公告）日：1997-04-15
• [EN] PHENOL DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE PHÉNOL ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CRYSTALGENOMICS INC

  公开号：WO2010018458A2

  公开（公告）日：2010-02-18

  Disclosed herein are hydroxyaryl or hydroxyheteroaryl derivative compounds, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, pharmaceutical compositions comprising the same, and methods of modulating the level or activity of HIF in a subject, inhibiting hydroxylation of HIFα in a subject, modulating expression of HIF-regulated genes in a subject, treating an HIF -related disorder in a subject, increasing levels of endogenous EPO in a subject, or treating a disorder in a subject, using the disclosed compounds.